From the Journals

Oral contraceptive use linked to lower rheumatoid arthritis risk


 

FROM ANNALS OF THE RHEUMATIC DISEASES

The use of oral contraceptives may be associated with a reduced risk of rheumatoid arthritis based on findings from a large, population-based, case-control study in Sweden.

oral contraceptives areeya_ann/Thinkstock
Previous research into the impact of OC use on RA risk had shown mixed results, with some studies finding an inverse association but most finding no association, the investigators noted. However, they pointed out that few of these studies looked at seropositivity either via rheumatoid factor or the presence or absence of ACPA.

“All of these findings together support the notion of RA as two different disease entities with different risk factors patterns,” the authors wrote.

The researchers looked at 2,578 women with RA and 4,129 female controls from the Swedish Epidemiological Investigation of RA study and found that women who had ever used OCs had 13% lower odds of developing RA than did women who had never used OCs, even after adjusting for age, residential area, smoking, and alcohol consumption. However, this association was significant only for ACPA-positive RA – where the risk was 16% lower – and not for ACPA-negative disease (Ann Rheum Dis. 2017 Aug 17. doi: 10.1136/annrheumdis-2017-211620).

Duration of oral contraceptive use was also positively associated with a decreased risk of RA; women who had taken OCs for 7 or more years had a 19% lower risk of RA, compared with never users.

However, the authors noted that they only collected information on the use of OCs as a whole and not on particular preparations or doses.

Women who had never used OCs and who had also smoked had more than twofold higher odds of developing RA than did women who had used OCs and who had never smoked. Women who had used OCs but who also smoked were 71% more likely to develop RA.

“Since both smoking and the use of OC have been linked to an increased predisposition to venous thrombotic events (VTE), women with a history of VTEs (especially if they smoke) might be recommended not to use OC by their physician. We can therefore not exclude the possibility that our findings on an interaction between non-OC use and smoking merely reflects that smoking women, who have an increased RA risk, do not receive OC prescription as often. The physiopathology of RA is complex and not fully understood, but our findings may contribute to the knowledge regarding mechanisms of importance for the development of RA,” the authors wrote.

The investigators also saw an influence of breastfeeding on the likelihood of developing RA, with a significant 23% lower odds for the disease among women who breastfed their children for 13 months or more and 7% lower odds in women who had breastfed their children for 7-12 months, compared with those who had breastfed for 0-6 months. Once again, this effect was only significant for ACPA-positive RA.

The study was supported by the Swedish Medical Research Council, the Swedish Research Council for Health, Working Life and Welfare, King Gustav V’s 80-Year Foundation, Vinnova, the Swedish Foundation for Strategic Research, the Swedish Rheumatic Foundation, the Stockholm County Council, the Insurance Company AFA, the Innovative Medicines Initiative, and the National Institutes of Health. The authors said that they had no competing interests.

Recommended Reading

Hemophilia carriers are at risk for abnormal bleeding
MDedge ObGyn
Birth outcomes unaffected by paternal immunosuppressive therapy
MDedge ObGyn
Unexplained subfertility in RA linked to periconceptional NSAID use
MDedge ObGyn
Study offers reassuring data on certolizumab use in pregnancy
MDedge ObGyn
Breast milk doesn’t contain meaningful levels of certolizumab pegol
MDedge ObGyn
Prenatal exposure to TNF inhibitors does not increase infections in newborns
MDedge ObGyn
U.S. chikungunya epidemic would likely put rheumatologists on front line
MDedge ObGyn
Stopping TNF inhibitors for pregnancy may invite flares
MDedge ObGyn
Safety of corticosteroids in pregnancy: Is it the drug or the disease?
MDedge ObGyn
Study sheds light on pregnancy outcomes following ocrelizumab treatment
MDedge ObGyn

Related Articles